There are currently 821 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Recruiting
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Indiana University and Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL)
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Indianapolis, Indiana
Conditions: Chronic Granulomatous Disease (CGD)
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Not set, Indianapolis, Indiana
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
Recruiting
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
05/30/2025
Locations: Riley Hospital for Children & Indiana University, Indianapolis, Indiana
Conditions: Cystic Fibrosis
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
05/30/2025
Locations: Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis, Indiana
Conditions: Crohn's Disease
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/30/2025
Locations: Research Site, Indianapolis, Indiana +1 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Recruiting
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week... Read More
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
05/30/2025
Locations: Indiana University Health University Hospital ( Site 5022), Indianapolis, Indiana
Conditions: Crohn's Disease
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Recruiting
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Collection of Tissue Samples for Cancer Research
Recruiting
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. * To obtain samples fo... Read More
Gender:
ALL
Ages:
2 months and above
Trial Updated:
05/30/2025
Locations: Indiana University - Purdue, Indianapolis, Indiana
Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Recruiting
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/30/2025
Locations: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2025
Locations: Vincent Medical Group, Indianapolis, Indiana
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants. Risankizumab is an approved drug for adults with CD. This study comprises... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: IU Health University Hospital /ID# 259633, Indianapolis, Indiana
Conditions: Crohn's Disease